Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1007/s13311-019-00775-8 http://hdl.handle.net/11449/189630 |
Resumo: | Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by extensive inflammation, demyelination, axonal loss and gliosis. Evidence indicates that mast cells contribute to immunopathogenesis of both MS and experimental autoimmune encephalomyelitis (EAE), which is the most employed animal model to study this disease. Considering the inflammatory potential of mast cells, their presence at the CNS and their stabilization by certain drugs, we investigated the effect of ketotifen fumarate (Ket) on EAE development. EAE was induced in C57BL/6 mice by immunization with MOG35-55 and the animals were injected daily with Ket from the seventh to the 17th day after disease induction. This early intervention with Ket significantly reduced disease prevalence and severity. The protective effect was concomitant with less NLRP3 inflammasome activation, rebalanced oxidative stress and also reduced T cell infiltration at the CNS. Even though Ket administration did not alter mast cell percentage at the CNS, it decreased the local CPA3 and CMA1 mRNA expression that are enzymes typically produced by these cells. Evaluation of the CNS-barrier permeability indicated that Ket clearly restored the permeability levels of this barrier. Ket also triggered an evident lymphadenomegaly due to accumulation of T cells that produced higher levels of encephalitogenic cytokines in response to in vitro stimulation with MOG. Altogether these findings reinforce the concept that mast cells are particularly relevant in MS immunopathogenesis and that Ket, a known stabilizer of their activity, has the potential to be used in MS control. |
id |
UNSP_ee9d9eb67431a84d6769a8321f7ea1af |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/189630 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy?Blood-CNS barrierExperimental autoimmune encephalomyelitisInflammasomeKetotifen fumarateMultiple sclerosisOxidative stressMultiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by extensive inflammation, demyelination, axonal loss and gliosis. Evidence indicates that mast cells contribute to immunopathogenesis of both MS and experimental autoimmune encephalomyelitis (EAE), which is the most employed animal model to study this disease. Considering the inflammatory potential of mast cells, their presence at the CNS and their stabilization by certain drugs, we investigated the effect of ketotifen fumarate (Ket) on EAE development. EAE was induced in C57BL/6 mice by immunization with MOG35-55 and the animals were injected daily with Ket from the seventh to the 17th day after disease induction. This early intervention with Ket significantly reduced disease prevalence and severity. The protective effect was concomitant with less NLRP3 inflammasome activation, rebalanced oxidative stress and also reduced T cell infiltration at the CNS. Even though Ket administration did not alter mast cell percentage at the CNS, it decreased the local CPA3 and CMA1 mRNA expression that are enzymes typically produced by these cells. Evaluation of the CNS-barrier permeability indicated that Ket clearly restored the permeability levels of this barrier. Ket also triggered an evident lymphadenomegaly due to accumulation of T cells that produced higher levels of encephalitogenic cytokines in response to in vitro stimulation with MOG. Altogether these findings reinforce the concept that mast cells are particularly relevant in MS immunopathogenesis and that Ket, a known stabilizer of their activity, has the potential to be used in MS control.Department of Microbiology and Immunology Institute of Biosciences São Paulo State University (UNESP), Rua Dr. Plinio Pinto e Silva, S/N, Distrito de Rubião JúniorDepartment of Chemistry and Biochemistry Institute of Biosciences São Paulo State University (UNESP)Department of Surgery Stomatology Pathology and Radiology Bauru School of Dentistry University of São Paulo (USP)Department of Microbiology and Immunology Institute of Biosciences São Paulo State University (UNESP), Rua Dr. Plinio Pinto e Silva, S/N, Distrito de Rubião JúniorDepartment of Chemistry and Biochemistry Institute of Biosciences São Paulo State University (UNESP)Universidade Estadual Paulista (Unesp)Universidade de São Paulo (USP)Pinke, Karen Henriette [UNESP]Zorzella-Pezavento, Sofia Fernanda Gonçalves [UNESP]de Campos Fraga-Silva, Thais Fernanda [UNESP]Mimura, Luiza Ayumi Nishiyama [UNESP]de Oliveira, Larissa Ragozo Cardoso [UNESP]Ishikawa, Larissa Lumi Watanabe [UNESP]Fernandes, Ana Angélica Henrique [UNESP]Lara, Vanessa SoaresSartori, Alexandrina [UNESP]2019-10-06T16:46:49Z2019-10-06T16:46:49Z2019-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1007/s13311-019-00775-8Neurotherapeutics.1878-74791933-7213http://hdl.handle.net/11449/18963010.1007/s13311-019-00775-82-s2.0-85072014546Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengNeurotherapeuticsinfo:eu-repo/semantics/openAccess2021-10-23T19:02:03Zoai:repositorio.unesp.br:11449/189630Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T15:53:23.336663Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? |
title |
Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? |
spellingShingle |
Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? Pinke, Karen Henriette [UNESP] Blood-CNS barrier Experimental autoimmune encephalomyelitis Inflammasome Ketotifen fumarate Multiple sclerosis Oxidative stress |
title_short |
Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? |
title_full |
Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? |
title_fullStr |
Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? |
title_full_unstemmed |
Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? |
title_sort |
Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? |
author |
Pinke, Karen Henriette [UNESP] |
author_facet |
Pinke, Karen Henriette [UNESP] Zorzella-Pezavento, Sofia Fernanda Gonçalves [UNESP] de Campos Fraga-Silva, Thais Fernanda [UNESP] Mimura, Luiza Ayumi Nishiyama [UNESP] de Oliveira, Larissa Ragozo Cardoso [UNESP] Ishikawa, Larissa Lumi Watanabe [UNESP] Fernandes, Ana Angélica Henrique [UNESP] Lara, Vanessa Soares Sartori, Alexandrina [UNESP] |
author_role |
author |
author2 |
Zorzella-Pezavento, Sofia Fernanda Gonçalves [UNESP] de Campos Fraga-Silva, Thais Fernanda [UNESP] Mimura, Luiza Ayumi Nishiyama [UNESP] de Oliveira, Larissa Ragozo Cardoso [UNESP] Ishikawa, Larissa Lumi Watanabe [UNESP] Fernandes, Ana Angélica Henrique [UNESP] Lara, Vanessa Soares Sartori, Alexandrina [UNESP] |
author2_role |
author author author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (Unesp) Universidade de São Paulo (USP) |
dc.contributor.author.fl_str_mv |
Pinke, Karen Henriette [UNESP] Zorzella-Pezavento, Sofia Fernanda Gonçalves [UNESP] de Campos Fraga-Silva, Thais Fernanda [UNESP] Mimura, Luiza Ayumi Nishiyama [UNESP] de Oliveira, Larissa Ragozo Cardoso [UNESP] Ishikawa, Larissa Lumi Watanabe [UNESP] Fernandes, Ana Angélica Henrique [UNESP] Lara, Vanessa Soares Sartori, Alexandrina [UNESP] |
dc.subject.por.fl_str_mv |
Blood-CNS barrier Experimental autoimmune encephalomyelitis Inflammasome Ketotifen fumarate Multiple sclerosis Oxidative stress |
topic |
Blood-CNS barrier Experimental autoimmune encephalomyelitis Inflammasome Ketotifen fumarate Multiple sclerosis Oxidative stress |
description |
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by extensive inflammation, demyelination, axonal loss and gliosis. Evidence indicates that mast cells contribute to immunopathogenesis of both MS and experimental autoimmune encephalomyelitis (EAE), which is the most employed animal model to study this disease. Considering the inflammatory potential of mast cells, their presence at the CNS and their stabilization by certain drugs, we investigated the effect of ketotifen fumarate (Ket) on EAE development. EAE was induced in C57BL/6 mice by immunization with MOG35-55 and the animals were injected daily with Ket from the seventh to the 17th day after disease induction. This early intervention with Ket significantly reduced disease prevalence and severity. The protective effect was concomitant with less NLRP3 inflammasome activation, rebalanced oxidative stress and also reduced T cell infiltration at the CNS. Even though Ket administration did not alter mast cell percentage at the CNS, it decreased the local CPA3 and CMA1 mRNA expression that are enzymes typically produced by these cells. Evaluation of the CNS-barrier permeability indicated that Ket clearly restored the permeability levels of this barrier. Ket also triggered an evident lymphadenomegaly due to accumulation of T cells that produced higher levels of encephalitogenic cytokines in response to in vitro stimulation with MOG. Altogether these findings reinforce the concept that mast cells are particularly relevant in MS immunopathogenesis and that Ket, a known stabilizer of their activity, has the potential to be used in MS control. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-10-06T16:46:49Z 2019-10-06T16:46:49Z 2019-01-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1007/s13311-019-00775-8 Neurotherapeutics. 1878-7479 1933-7213 http://hdl.handle.net/11449/189630 10.1007/s13311-019-00775-8 2-s2.0-85072014546 |
url |
http://dx.doi.org/10.1007/s13311-019-00775-8 http://hdl.handle.net/11449/189630 |
identifier_str_mv |
Neurotherapeutics. 1878-7479 1933-7213 10.1007/s13311-019-00775-8 2-s2.0-85072014546 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Neurotherapeutics |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808128579277422592 |